{"id":"NCT01663727","sponsor":"Hoffmann-La Roche","briefTitle":"Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer","officialTitle":"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-08-27","primaryCompletion":"2014-11-30","completion":"2017-11-21","firstPosted":"2012-08-13","resultsPosted":"2016-02-10","lastUpdate":"2019-01-22"},"enrollment":481,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Breast Cancer"],"interventions":[{"type":"DRUG","name":"Bevacizumab [Avastin]","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"A","type":"EXPERIMENTAL"},{"label":"B","type":"EXPERIMENTAL"}],"summary":"This is a Phase III, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of bevacizumab administered in combination with paclitaxel in patients with previously untreated, locally recurrent, or metastatic HER2-negative breast cancer. Patients will be randomized to one of two treatment arms: bevacizumab or placebo. All patients will be given an intravenous (IV) infusion of of paclitaxel (90 mg/m2) for 3 weeks during each 28-day cycle. bevacizumab or placebo (10 mg/kg) will be administered by IV infusion on Days 1 and 15 of each 28-day cycle. Patients will be treated until disease progression, unacceptable toxicity or death from any cause occurs.","primaryOutcome":{"measure":"Percentage of Participants With Progression or Death in Intent-to-Treat (ITT) Population","timeFrame":"Baseline, every 8 weeks until documented disease progression, death or clinical cut-off (up to 117.7 weeks)","effectByArm":[{"arm":"Paclitaxel+Placebo","deltaMin":69.4,"sd":null},{"arm":"Paclitaxel+ Bevacizumab","deltaMin":63.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":11},"locations":{"siteCount":178,"countries":["United States","Argentina","Belgium","Brazil","Bulgaria","Chile","Germany","Italy","Japan","Panama","Romania","Russia","South Africa","South Korea","Ukraine","United Kingdom"]},"refs":{"pmids":["28158579","27817944"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":45,"n":233},"commonTop":["Alopecia","Peripheral sensory neuropathy","Nausea","Fatigue","Diarrhoea"]}}